ATE857T1 - Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine. - Google Patents

Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine.

Info

Publication number
ATE857T1
ATE857T1 AT79104391T AT79104391T ATE857T1 AT E857 T1 ATE857 T1 AT E857T1 AT 79104391 T AT79104391 T AT 79104391T AT 79104391 T AT79104391 T AT 79104391T AT E857 T1 ATE857 T1 AT E857T1
Authority
AT
Austria
Prior art keywords
membrane proteins
neisseria meningitidis
production
vaccine containing
optionally
Prior art date
Application number
AT79104391T
Other languages
German (de)
English (en)
Inventor
Torsten Bertil Dr. Helting
Gerhard Dr. Guthoehrlein
Original Assignee
Behringwerke Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Aktiengesellschaft filed Critical Behringwerke Aktiengesellschaft
Application granted granted Critical
Publication of ATE857T1 publication Critical patent/ATE857T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT79104391T 1978-11-11 1979-11-08 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine. ATE857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
EP79104391A EP0011243B1 (de) 1978-11-11 1979-11-08 Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine

Publications (1)

Publication Number Publication Date
ATE857T1 true ATE857T1 (de) 1982-04-15

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT79104391T ATE857T1 (de) 1978-11-11 1979-11-08 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine.

Country Status (9)

Country Link
EP (1) EP0011243B1 (enrdf_load_stackoverflow)
JP (1) JPS5566519A (enrdf_load_stackoverflow)
AT (1) ATE857T1 (enrdf_load_stackoverflow)
AU (1) AU533386B2 (enrdf_load_stackoverflow)
CA (1) CA1142083A (enrdf_load_stackoverflow)
DE (2) DE2848965A1 (enrdf_load_stackoverflow)
DK (1) DK154841C (enrdf_load_stackoverflow)
ES (1) ES485715A1 (enrdf_load_stackoverflow)
IL (1) IL58673A (enrdf_load_stackoverflow)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
EP0127681B1 (en) * 1982-12-02 1993-03-03 The Rockefeller University Iga binding protein
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
BR9910749A (pt) 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2003260357B2 (en) 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
CA2550927A1 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP5275982B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AU2008313424B2 (en) 2007-10-19 2014-05-22 Novartis Ag Meningococcal vaccine formulations
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
WO2011110634A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
NZ630133A (en) 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
WO2014044728A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
MX2021005303A (es) 2018-11-06 2021-07-07 Glaxosmithkline Biologicals Sa Composiciones inmunogenicas.
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
IL58673A (en) 1983-02-23
DK154841B (da) 1988-12-27
EP0011243A1 (de) 1980-05-28
AU5268279A (en) 1980-05-15
DE2848965A1 (de) 1980-05-22
DK154841C (da) 1989-06-05
DK475779A (da) 1980-05-12
IL58673A0 (en) 1980-02-29
JPS5566519A (en) 1980-05-20
DE2962526D1 (en) 1982-05-27
JPS6350332B2 (enrdf_load_stackoverflow) 1988-10-07
CA1142083A (en) 1983-03-01
AU533386B2 (en) 1983-11-24
EP0011243B1 (de) 1982-04-14
ES485715A1 (es) 1980-05-16

Similar Documents

Publication Publication Date Title
ATE857T1 (de) Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine.
ATE195420T1 (de) Methode zur herstellung von eicosapentansäuren
DE69224124D1 (de) Verfahren zur Herstellung von Dihomo-Gamma-Linolensäure und das in dieser enthaltende Lipid
DE3767077D1 (de) Verfahren zur abtrennung von cholesterin aus fettsubstanzen tierischen ursprungs und cholesterinarme fettsubstanzen.
DE68906385D1 (de) Verfahren und vorrichtung zur reinigung von wasser mittels polypyrrolidon.
ATE69927T1 (de) Verfahren zur herstellung eines molkeproduktes mit verringerter allergenitaet.
DE3675239D1 (de) Verfahren zur herstellung von aminopropylalkoxysilanen.
ATE944T1 (de) Verfahren zur herstellung von knochenersatzmaterial mit verbesserter biologischer stabilitaet auf der basis von kollagen und das erhaltene knochenersatzmaterial.
ATE18845T1 (de) Tierstreu sowie verfahren zu ihrer herstellung.
ATE123947T1 (de) Echinacea-extrakte, verfahren zur herstellung und zubereitungen, die sie enthalten.
DE60107446D1 (de) Gereinigtes cochinealpigment und verfahren zur herstellung desselben
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
ATE70452T1 (de) Verfahren zur herstellung eines propolis|thanolextraktes.
EP0607593A3 (de) Verfahren zur Gewinnnung von Zellkulturen mit erhöhtem Gehalt an körpereigenen Zytokinen.
ATE30161T1 (de) Verfahren zur herstellung von globin aus haemoglobin und das in diesem verfahren erhaltene globin.
ATE92056T1 (de) Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.
ATE215784T1 (de) Verfahren zur herstellung eines kappa-casein- glykomakropeptides oder eines abkoemmlings davon
ATE116989T1 (de) Verfahren zur reinigung von hemin, neues heminderivat und verfahren zur herstellung.
ATE14596T1 (de) Verfahren zur herstellung von ammoniumlactat enthaltenden mischungen und vorrichtung zur durchfuehrung des verfahrens.
FR2620726B1 (fr) Procede de preparation d'un extrait de jasmin et extrait obtenu
FR2429765A1 (fr) Procede et agent d'adsorption pour isoler des enzymes et pour les preparer a l'etat pur
ATE101393T1 (de) Phenanthridinderivate, verfahren zu ihrer herstellung und mittel zur ausfuehrung des verfahrens.
ATE69034T1 (de) Verfahren zur herstellung von polychlorophosphazen.
DE59106227D1 (de) Verfahren zur herstellung von spagyrischen essenzen aus pflanzen.
JPS6410950A (en) Elimination of taste and odor of substance rich in amino acid

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time